Hep C Treatment

BC's PharmaCareGeneral Information

BC’s PharmaCare helps residents of British Columbia with the cost of eligible prescription drugs and certain medical supplies. It provides access to drug therapy through several drug plans.

Although BC has a couple of PharmaCare plans that residents may qualify for—for example, Plan C for those receiving income assistance—most BC residents are covered under Fair PharmaCare. Coverage under this plan is based on your family’s net income. It is available to single people or to families. Register for Fair PharmaCare online. You only need to register once. Your coverage is updated on January 1 of every year based on your current income information.

Limited Coverage Drugs

While hepatitis C is still considered a limited coverage drug, as of March 13 2018, any British Columbian living with chronic hepatitis C now is able to access treatment, regardless of the severity of their disease.

The only restrictions – the only way one wouldn’t be eligible for PharmaCare treatment for hepatitis C – are if a person is at high-risk for not taking the full treatment every day for as long as it is prescribed OR if someone is already being treated for hep C.

Special Authority Access

To get coverage for limited coverage drugs a hepatitis C specialist – a healthcare provider experienced with treating hep C – submits a Special Authority request for coverage on behalf of the patient. The request is reviewed by a BC PharmaCare committee and, if approved, the specialist can then write a prescription for the drug/s.

Talk to your healthcare provider for more information or to start the treatment process.

BC PharmaCare Covered Hep C Treatments

Targeted Genotypes Additional Notes PharmaCare Covered Treatment Options* Possible Lengths of Treatment
1 – 6 Epclusa (sofosbuvir/velpatasvir) 12 weeks
1 All of these treatments are for those who have OR haven’t already tried treatment. Harvoni is the preferable treatment. Galexos (simeprevir) taken in combination with pegylated interferon with ribavirin (PR) 24 – 48 weeks
Sovaldi (sofosbuvir) taken in combination with pegylated interferon with ribavirin (PR) 12 weeks
Harvoni (ledipasvir and sofosbuvir) 8 – 24 weeks
1, 4 Zepatier (elbasvir and grazoprevir) 12 – 16 weeks
1 Sunvepra (asunaprevir) 24 weeks
3 Works against hep C in combination with other DAAs. Daklinza (daclatasvir) 12 weeks
2, 3 These treatments are for those who haven’t tried treatment (treatment-naive) AND who don’t have medical reasons against taking interferon. Pegylated interferon with ribavirin (PR) 14 or 24 weeks according to genotype
2, 3 These treatments are for those who are treatment-naive with medical reason against interferon OR are PR treatment- experienced Sovaldi (sofosbuvir) in combination with ribavirin (Ibavyr) 12 weeks for genotype 2
24 weeks for genotype 3
2 – 6 Pegylated interferon with ribavirin 14 or 24 weeks
1-6/1-4 Without cirrhosis or with compensated cirrhosis, who have: genotype 1, 2, 3, 4, 5, or 6 infection and have previously been treated with an HCV regimen containing an NS5A inhibitor;W OR genotype 1, 2, 3, or 4 infection and have been previously treated with an HCV regimen containing SOF without an NS5A inhibitor Vosevi

(sofosbuvir/velpatasvir/voxilaprevir)

12 weeks
*Please see Comparing Hep C Treatments or the individual treatment pages for more information about the treatments and how one may be eligible for BC PharmaCare treatment coverage.
Targeted Genotypes Additional Notes PharmaCare Covered Treatment Options* Possible Lengths of Treatment
1 – 6 Epclusa (sofosbuvir/velpatasvir) 12 weeks
1 All of these treatments are for those who have OR haven’t already tried treatment. Harvoni is the preferable treatment. Galexos (simeprevir) taken in combination with pegylated interferon with ribavirin (PR) 24 – 48 weeks
Sovaldi (sofosbuvir) taken in combination with pegylated interferon with ribavirin (PR) 12 weeks
Harvoni (ledipasvir and sofosbuvir) 8 – 24 weeks
1, 4 Zepatier (elbasvir and grazoprevir) 12 – 16 weeks
1 Sunvepra (asunaprevir) 24 weeks
3 Works against hep C in combination with other DAAs. Daklinza (daclatasvir) 12 weeks
2, 3 These treatments are for those who haven’t tried treatment (treatment-naive) AND who don’t have medical reasons against taking interferon. Pegylated interferon with ribavirin (PR) 14 or 24 weeks according to genotype
2, 3 These treatments are for those who are treatment-naive with medical reason against interferon OR are PR treatment- experienced Sovaldi (sofosbuvir) in combination with ribavirin (Ibavyr) 12 weeks for genotype 2
24 weeks for genotype 3
2 – 6 Pegylated interferon with ribavirin 14 or 24 weeks
*Please see Comparing Hep C Treatments or the individual treatment pages for more information about the treatments and how one may be eligible for BC PharmaCare treatment coverage.

If you don’t have PharmaCare coverage

If you have lost or never had PharmaCare coverage, you’ll need to do these things:

  • make sure your income taxes are up-to-date
  • apply for BC PharmaCare coverage

Our Financial Support page includes information about financial support for those interested in DAA treatments that aren’t covered by PharmaCare. The page lists all of the Canadian financial assistance programs.

If you have private health insurance, consult with a representative from the company to find out specific coverage details for hep C treatments. Many insurance companies follow the provincial PharmaCare coverage guidelines and only cover treatments that are PharmaCare approved, but check individual policies for details, as others cover all of the treatments approved for use in Canada.

Information about Individual Treatments and Coverage

Information about treatments and coverage details can be found following the treatment links within the above table or at Comparing Hep C Treatments.